$ cat ./records/gates-foundation-and-wellcome-trust-jointly-fund-ebola-vaccine-an-2014.txt
Gates Foundation and Wellcome Trust Jointly Fund Ebola Vaccine and Therapeutics Research
[RECORD.TXT] · cat --full
The Gates Foundation and Wellcome Trust co-ordinated their Ebola research investments during the 2014–2015 outbreak, jointly financing accelerated clinical trials for vaccine candidates and therapeutic approaches. Wellcome's funding directly supported trials for the rVSV-ZEBOV vaccine (which would become Ervebo) while the Gates Foundation funded parallel tracks on diagnostics, healthcare worker training, and alternative vaccine platforms. The collaboration between the two largest private global health funders was credited with compressing timelines that would otherwise have taken a decade into a 24-month emergency sprint.
Source: https://wellcome.org/news/landmark-moment-fight-against-ebola-what-have-we-learnt
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Joins Global Health Security Agenda to Strengthen 70-Nation Outbreak Detection
Next →
Gates Foundation Funds Ebola Health Worker Training Across West Africa
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.